“Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies”, J of Skin, vol. 9, no. 6, p. s646, Nov. 2025, doi: 10.25251/ta5v8k92.